Currently, there are 42.75M common shares owned by the public and among those 36.60M shares have been available to trade.
Insiders at the company have transacted a total of 17 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 1,469,250 shares. Insider sales of the common stock occurred on 9 occasions, with total insider shares sold totaling 651,441 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 35.61, up 84.62%. The company’s stock has a 5-day price change of 79.19% and 199.81% over the past three months. FDMT shares are trading 59.38% year to date (YTD), with the 12-month market performance up to 40.09% higher. It has a 12-month low price of $9.44 and touched a high of $24.10 over the same period. FDMT has an average intraday trading volume of 403.13K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 75.95%, 87.63%, and 97.37% respectively.
Institutional ownership of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) shares accounts for 87.42% of the company’s 42.75M shares outstanding.
It has a market capitalization of $1.38B and a beta (3y monthly) value of 2.61. The earnings-per-share (ttm) stands at -$2.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.46% over the week and 6.85% over the month.
Analysts forecast that 4D Molecular Therapeutics Inc (FDMT) will achieve an EPS of -$0.74 for the current quarter, -$0.83 for the next quarter and -$3.1 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.87 while analysts give the company a high EPS estimate of -$0.41. Comparatively, EPS for the current quarter was -$0.84 a year ago. Earnings per share for the fiscal year are expected to increase by 21.55%, and -17.62% over the next financial year. EPS should grow at an annualized rate of -9.50% over the next five years, compared to -49.09% over the past 5-year period.
Looking at the support for the FDMT, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Outperform rating for the stock in a research note on October 26, 2023, with the firm’s price target at $25.
